id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-5256-0005,FDA,FDA-2019-E-5256,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T13:26:57Z,,0,0,090000648636562d
FDA-2019-E-5256-0004,FDA,FDA-2019-E-5256,Determination of Regulatory Review Period for Purposes of Patent Extension; SEYSARA,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:19:46Z,2023-27003,0,0,09000064863165a2